Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE) - O'Donoghue, Michelle L.; G． López, J. Antonio; Knusel, Beat; Gencer, Baris; Wang, Huei; Wu, You; Kassahun, Helina; Sabatine, Marc S. (The American heart journal, 2022)
Keywords: Apolipoproteins; Arteriosclerosis; Atherosclerosis; Cardiovascular disease; Cardiovascular diseases; Cerebrovascular disease; Clinical trials; Design; Dosage; Drug dosages; Health risks; Hepatocytes; Lipoproteins; Placebos; Plasma; Reduction; Risk analysis; Risk factors; siRNA; Japan